Skip to main content

Table 5 Summary of key inputs and outputs

From: Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians

 

Frequentist approach

Bayesian approach

Is the network of evidence sparse? (<5 studies)

Works well

Does not work well for standard non-informative priors but works well for informative priors

Non-informative priors could result in unrealistically wide credible intervals

Is prior specification justified?

No priors used—based solely on observed data

Non-informative if enough data are available, informative in the case of sparse data, choice of suitable distributions and additional information such as expert clinician opinion

Are there few large studies of high quality?

Consider FE model

Consider FE model

Are there country-specific regulations?

Required by German G-BA and Australian PBAC

Preferred by NICE in the UK

Interpretation

Statistical significance or the absence thereof

One treatment favorable/unfavorable over another treatment, or two treatments comparable

Often falsely interpreted as significant or not significant; common misconception

  1. FE fixed effects, G-BA Federal Joint Committee, NICE National Institute for Health and Care Excellence, PBAC Pharmaceutical Benefits Advisory Committee